Heyde syndrome
Heyde syndrome: aortic valve replacement as a treatment for lower gastrointestinal bleeding
Keywords:
Lower gastrointestinal bleeding, Heyde Syndrome, Von Willebrand Factor, Aortic Stenosis, Angiodysplasia, Intestinal bleeding, Aortic valve replacementAbstract
Lower Gastrointestinal Bleeding (LGB) is defined as gastrointestinal bleeding distal to the angle of Treitz. In many situations, the clinical presentation of a gastrointestinal bleeding does not allow elucidating its origin. LGB can manifest in the form of hematochezia or rectal bleeding, and of the total number of patients with LGB, the highest percentage are from the colon in aprox. 75% of cases, being less frequent the upper gastrointestinal tract. Among the main causes of LGB are colonic diverticulosis and angiodysplasia, which are more prevalent in older patients.
Heyde Syndrome is a rare diagnosis, first described in 1958. It is the association of gastrointestinal bleeding due to angiodysplasia and aortic stenosis, both being a degenerative process due to an acquired deficiency of von Willebrand Factor (vWF), type IIA.
The objective of this presentation is to present a rare cause of LGB such as Heyde Syndrome, whose definitive treatment consists in aortic valve replacement
Downloads
References
ZINMAN, Bernard et al. Semaglutida una vez a la semana como complemento de la terapia con inhibidores de SGLT-2 en la diabetes tipo 2 (SUSTAIN 9): un estudio aleatorizado, controlado con placebo. The Lancet Diabetes & Endocrinology, v. 7, n. 5, páginas 356-367, 2019.
Davies MJ, Bergenstal R, Bode B, et al. Eficacia de liraglutida en el tratamiento de la diabetes tipo 2 en un ensayo controlado aleatorio. Cuidado de la diabetes. 2021;34(9):2043-2050. DOI: 10.2337/DC11-0070.
Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cellular Metabolism. 2018;27(4):740-756.
FDA. FDA aprova novo tratamento para diabetes tipo 2. 2012. Disponível em: https://www.fda.gov/news-events/press-announcements/fda-approves-new- treatment-type-2-diabetes-0 . Acesso em: 09 mar. 2023.
MORAES, Carolina de Almeidaet al. Obesidad y diabetes: una revisión de los principales estudios. Revista Científica FHO| UNIARARAS, v. 3, n. 1, p. 1-8, 2019.
WILDING, John PH et al. Semaglutida una vez a la semana en adultos con sobrepeso u obesidad. New England Journal of Medicine, v. 384, n. 11, p. 989- 1002, 2021. Ver más
WuT, y otros. Eficacia y seguridad de liraglutida en pacientes obesos: una revisión sistemática y metanálisis de ensayos clínicos aleatorizados. Diabetes Obes Metab. 2021;23(7):1468-1477. doi: 10.1111/dom.14333.
Holst JJ, Vilsbøll T, Deacon CF, Krarup T. Seguridad y tolerabilidad de los agonistas del receptor del péptido-1 similares al glucagón: problemas emergentes y no resueltos. Nat Rev Endocrinol. 2019 Julio;15(7):405-418. DOI: 10.1038/s41574-019-0194-2. PMID: 31097790.
García A, Martínez B, López C, et al. Associação entre Agonistas do Receptor GLP-1 e Ideação Suicida: Um Estudo Prospectivo. Eur J Endocrinol. 2022;177(3):215-222. doi: 10.1530/EJE-22-0123.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Víctor Raúl Luraschi Centurión, Rita Monthzerrat Miranda Vergara, Roun Kim
This work is licensed under a Creative Commons Attribution 4.0 International License.
Todo el contenido de esta revista, está bajo 